Solid Tumor
Show Only Open Trials
1.
CALGB 70807: The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
- Study Status: Open to Enrollment
- Sponsor: CALGB
2.
E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
- Study Status: Open to Enrollment
- Sponsor: Eastern Cooperative Oncology Group
3.
REO 022: A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) in Patients with Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer
- Study Status: Open to Enrollment
- Sponsor: Oncolytics Biotech, Inc.
- Disease Status and/or Stage: Colon Cancer
4.
REO 017: A Phase 2 Study of Reolysin® in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Advanced or Metastatic Pancreatic Cancer
5.
A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects with Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
- Study Status: Closed to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Advanced/Metastatic Renal Cell Carcinoma (RCC)
6.
A Phase II Study of Tetrathiomolybdate (TM) in patients with breast cancer at moderate to high risk of recurrence
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: High-Risk Stage II Breast Cancer; Stage III Breast Cancer; Stage IV Breast Cancer in Remission
7.
S0221: Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
- Study Status: Closed to Enrollment
- Sponsor: SouthWest Oncology Group (SWOG) and The Cancer Support Trials Unit (CTSU)
- Disease Status and/or Stage: Operable Stage 1, II or II Invasive Breast Cancer
8.
Prospective Data Collection Among Women Using Cold Caps During TC Chemotherapy
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Early-Stage Breast Cancer
9.
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy
- Study Status: Open to Enrollment
- Sponsor: Lilly
- Disease Status and/or Stage: Stage IV Non-Small Cell Lung Cancer
10.
A Phase 1b Safety Study of Abiraterone Acetate (JNJ 212082) and Docetaxel in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (COU-AA-206)
- Study Status: Open to Enrollment
- Sponsor: Cougar Biotechnology
- Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
11.
12.
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B, National Cancer Institute
- Disease Status and/or Stage: High Risk, Clinically Localized Prostate Cancer
13.
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Castration-Resistant Prostate Cancer
14.
A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients with Metastatic Androgen-Independent Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic, Hormone-Refractory Prostate Cancer
15.
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed Prostate Cancer
16.
A Phase I Trial of Docetaxel/Prednisone plus Fractionated 177Lu-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients with Metastatic, Castrate-Resistant Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Prostate Cancer
17.
A Phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy
- Study Status: Open to Enrollment
- Sponsor: Radiation Therapy Oncology Group, National Cancer Institute
- Disease Status and/or Stage: Prostate Cancer After Radical Prostatectomy
18.
A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors
- Study Status: Closed to Enrollment
- Sponsor: BiPar Sciences
- Disease Status and/or Stage: Metastatic Pancreatic Cancer
19.
A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.
- Study Status: Closed to Enrollment
- Sponsor: Immunomedics, Inc.
- Disease Status and/or Stage: Untreated Advanced Pancreatic Cancer
20.
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Study Status: Open to Enrollment
- Sponsor: GlaxoSmithKline
- Disease Status and/or Stage: Ovary, Primary Peritoneal or Fallopian Tube Cancer
21.
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxila) in Patients with Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated with a Taxane
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Advanced Epithelial Ovarian Cancer or Peritoneal Cancer
22.
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
- Study Status: Open to Enrollment
- Sponsor: Tragara Pharmaceuticals
- Disease Status and/or Stage: Stage IIIB/IV or Recurrent, Unresectable Non-Small Cell Lung Cancer
23.
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM)
- Study Status: Open to Enrollment
- Sponsor: Eli Lily & Co.
- Disease Status and/or Stage: Unresectable, Locally Advance, Stage III Non-Small Cell Lung Cancer
24.
A Phase I/II Study of Vorinostat in Combination with Isotretinoin in the Treatment of Patients with Advanced Renal Cell Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College, National Cancer Institute
- Disease Status and/or Stage: Metastatic or Advanced Kidney Cancer
25.
A Phase I/II Trial of BAY 43-9006 plus Gemcitabine and Capecitabine in the Treatment of Patients with Advanced Renal Cell Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College, National Cancer Institute
- Disease Status and/or Stage: Advanced, Unresectable and/or Metastatic Kidney Cancer
26.
ECOG 2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (RCC)
- Study Status: Closed to Enrollment
- Sponsor: Eastern Cooperative Oncology Group
- Disease Status and/or Stage: Renal Cell Cancer
27.
A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer
- Study Status: Open to Enrollment
- Sponsor: Mayo Clinic, National Cancer Institute
- Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
28.
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B (CALGB); National Cancer Institute (NCI)
- Disease Status and/or Stage: Advanced Transitional Cell Carcinoma
29.
A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Solid Tumor
30.
A Phase I/II, Open-Label, Dose Escalation Study of CDX-1401 in Patients with Malignances Known to Express NY-ESO-1
- Study Status: Closed to Enrollment
- Sponsor: Celldex Therapeutics
- Disease Status and/or Stage: Progressive Disease after therapies with curative potential or approved salvage regimen
31.
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients with Advanced Breast Cancer
- Study Status: Open to Enrollment
- Sponsor: Eisai
- Disease Status and/or Stage: Advanced Breast Cancer and Neuropathy
32.
E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
- Study Status: Open to Enrollment
- Sponsor: Eastern Cooperative Oncology Group; National Cancer Institute
- Disease Status and/or Stage: Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
33.
A Phase I-II Study of R115777 (Tipifarnib, Zarnestraâ) Plus Sequential Weekly Paclitaxel followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer
- Study Status: Open to Enrollment
- Sponsor: New York Cancer Consortium; National Cancer Institute
- Disease Status and/or Stage: Stage IIB-IIC Breast Cancer
34.
Phase II study of ixabepilone in patients with metastatic breast cancer and a prospective evaluation of its effects on the ultrastructure of neurons
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College; Bristol-Myers Squibb
- Disease Status and/or Stage: Metastatic Breast Cancer
35.
ACOSOG Z1072: A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma
- Study Status: Open to Enrollment
- Sponsor: American College of Surgeons/National Cancer Institute
- Disease Status and/or Stage: Invasive Breast Cancer
36.
A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer
- Study Status: Closed to Enrollment
- Sponsor: GlaxoSmithKline
- Disease Status and/or Stage: Metastatic Breast Cancer
37.
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism (VTE) in Patients with Cancer
- Study Status: Closed to Enrollment
- Disease Status and/or Stage: Any Stage of Cancer
38.
A Randomized Placebo-Controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients with a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Breast Cancer, any stage
39.
A Phase II Study of Tetrathiomolydate (TM) in patients with breast cancer at moderate to high risk for recurrence
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Breast Cancer at moderate to high risk of recurrence (based on the number of lymph nodes); Stage 4 breast cancer without any evidence of disease
